Barbara Killian

[bit.bio @bitbio]

Interested in developing in vitro models for your #raredisease research? Join #bitbio and speakers from @CureSHANK, @CRiverLabs and @healx on Thurs 13 August (17:00 BST) to learn more about the use of in vitro models in #preclinical testing. Register here: https://t.co/oeYXW3eFVM

[Charles River Labs @CRiverLabs]

Is it possible for two sisters to have the same rare genetic disorder? Ask Cate and Laura Cheevers. They are both living with #cysticfibrosis. Listen to their unique tales of living with CF in our latest episode of #VitalScience™ #podcast. https://t.co/p7YfwtJBUq

[Charles River Labs @CRiverLabs]

Seeking to inhibit #COVID19 protease? Test your compound in vitro with a COVID-19 specific protease inhibition assay. Protease inhibition assays have proven to be predictive first steps in antiviral screens for HIV and other viral research. https://t.co/3Xzr0uaU9S

[Charles River Labs @CRiverLabs]

★ Just published a new episode of Vital Science: Two in the Same. Listen: https://t.co/4BgtJWAkt8

[Bronson Health Foundation @BHFBronson]

Thank you @CRiverLabs for sponsoring respite rooms this week across our system! Respite rooms provide an area for a restful break for our healthcare heroes. Learn more here: https://t.co/O2Pth1RspC

[Rich Horgan @RichHorgan]

Great day at @US_FDA CBER session with @CRiverLabs' Lauren Black advocating for the advancement of #customizedtherapeutic development. Very glad to see that #CBER is listening to our collective needs. Now to get the payers on board...

[Barbara Killian @BarbaraKillia13]

#RDDNIH Twitter Trend : The Most Popular Tweets | United States https://t.co/7NaQ245bVh

[Red Sox @RedSox]

🚨GIVEAWAY ALERT🚨

RT now for a chance to win this Xander signed jersey!

[Charles River Labs @CRiverLabs]

The link between #neuroinflammation and a number of stubborn #CNS diseases is growing. Our #EurekaBlog is LIVE from #SfN19. Stay tuned for our continued coverage. https://t.co/eRtuem6svq

[Charles River Labs @CRiverLabs]

With the shift to #RNA based targets comes the need of developing new techniques or adapting existing ones to formats that would allow for high-throughput screens. Learn more from our HTS specialists at #SfN19 Booth 1043. https://t.co/1ScMc0UX4b

[MIT Sloan School of Management @MITSloan]

“I learned a lot on how to not treat people, and conversely, the importance of listening and respecting and appreciating your team.” @CRiverLabs https://t.co/wa9v5W4Nu8

[Charles River Labs @CRiverLabs]

In the wake of amyloid beta, companies eye tau and #neuroinflammation as #Alzheimer’s drug targets. Watch as our #EurekaBlog discusses alternatives in #dementia research from #SfN19. https://t.co/5aPkZSU9kL

[Charles River Labs @CRiverLabs]

What is the state of antisense oligonucleotides therapies? Our #EurekaBlog roundtable discussion explains how ASOs are moving from obscurity to a viable drug strategy. Our #SfN19 coverage continues. https://t.co/GIbPifeZaf

[Barbara Killian @BarbaraKillia13]

@CRiverLabs Counting down to #Sfn19

[Charles River Labs @CRiverLabs]

Thank you to @timyu and his team at @BostonChildrens, as well as @stopbatten for their incredible efforts. We are so proud to have been a part of this groundbreaking journey.

[Tim Yu @timyu]

2/3 Congrats to lead authors @jinkukkim & April Hu. Proud of the pioneering support from colleagues at @BostonChildrens as well as @ChildrensColo, @NUFeinbergMed, @UR_Med, @harvardmed, @CRiverLabs, @TriLinkBioTech, BrammerBio, @US_FDA, and many more.

[Charles River Labs @CRiverLabs]

Can you describe your scientific poster in just 6 words? Comment below with your poster number and tag your response with #CR6Words. See you at #SfN19, booth 1043. Need examples? Our scientists’ short and sweet titles hint at what you’ll find at #SFN19. https://t.co/9bVGY0agEZ

[Charles River Labs @CRiverLabs]

Congratulations to Allyson Berent and the GenetX team on their partnership with Ultragenyx. Hear Allyson talk about the personal journey of drug development at #CRLWorldCon. Register today! https://t.co/gNXQOR6yDV

[Charles River Labs @CRiverLabs]

Attending #IOSummit? We are pleased to participate in this year's program. With 61 patents, 17 preclinical candidates, and work on 88% of the cancer therapies approved in 2018, we’ll keep you moving at the speed of oncology. https://t.co/8w1wYhQSVt

[Charles River Labs @CRiverLabs]

Grant Wishart shares his expert opinion regarding #AI in drug discovery in a Q&A with Tamlyn Oliver @Biocompare https://t.co/Ad49Wy6PiT #artificialintelligence #machinelearning